Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Weber Says Takeda Made “Big Decision” to Pull Plug on Metabolic R&D
January 14, 2016
- Iwaki Top Brass to Return Remunerations over Embezzlement Issue
January 14, 2016
- Mundipharma Looks to Double Japan Sales of OTC Isodine Products in 5 Years
January 14, 2016
- Lenvima Filed for RCC Indication in EU: Eisai
January 13, 2016
- Enbrel Biosimilar Meets Equivalence Criteria in Global PIII: Daiichi Sankyo
January 13, 2016
- Takeda Allies with Canada’s enGene to Develop GI Disease Therapies
January 13, 2016
- Takeda, US Biotech NsGene Team Up on Cell Encapsulation Therapies for Parkinson’s
January 12, 2016
- Otsuka Files Leukemia Drug Ponatinib in Japan
January 12, 2016
- Lilly Japan, Torii Link Up to Copromote Psoriasis Drug Ixekizumab
January 12, 2016
- Astellas, Boehringer Extend Copromotion Pact for Micardis
January 8, 2016
- Sanofi Launches Japan PIII on Vaccine for C. Diff Infection
January 8, 2016
- Nippon Shinyaku Files Japan NDA for PAH Drug Selexipag
January 8, 2016
- Toray Enters Field of Nucleic Acid Medicine through Tie-Up with Bonac
January 8, 2016
- Belsomra Most Heavily Pitched Drug in November: Anterio
January 7, 2016
- Novartis, Chugai to Close Out Comarketing Scheme for Femara
January 7, 2016
- Takeda, French Startup Tie Up on Gut Bacteria-Derived Drugs for GI Disorders
January 7, 2016
- Selexipag Now Available in US: Nippon Shinyaku
January 6, 2016
- Generic Use Rate at 54.7% in July-September 2015: JGA
January 6, 2016
- Fuji Pharma Licenses Nesp Biosimilar from S. Korean Firm
January 6, 2016
- Blopress, Takepron to Go to Teva-Takeda Joint Venture
January 5, 2016
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…